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Abstract
Objectives—Some Asian countries have been reluctant to adopt Haemophilus influenzae type b 
(Hib) conjugate vaccination because of uncertainty over disease burden. We assessed the impact 
of introduction of Hib conjugate vaccine into the Expanded Program on Immunization in 
Bangladesh on purulent and laboratory-confirmed H influenzae meningitis.
Study design—Within a well-defined catchment area around 2 surveillance hospitals in Dhaka, 
Bangladesh, we compared the incidence of Hib meningitis confirmed by culture, latex 
agglutination, and polymerase chain reaction assay among infants 1 year before and 1 year after 
introduction of Hib conjugate vaccine. We adjusted the incidence rate for the proportion of 
children who sought care at the surveillance hospitals.
Results—Among infants, the incidence of confirmed Hib meningitis decreased from 92-16 cases 
per 100 000 within 1 year of vaccine introduction (vaccine preventable incidence = 76; 95% CI 
18, 135 per 100 000). The incidence of purulent meningitis decreased from 1659-1159 per 100 
000 (vaccine preventable incidence = 500; 95% CI: 203, 799 per 100 000). During the same time 
period, there was no significant difference in the incidence of meningitis due to Streptococcus 
pneumoniae.
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Conclusions—Introduction of conjugate Hib conjugate vaccine into Bangladesh Expanded 
Program on Immunization markedly reduced the burden of Hib and purulent meningitis.
Globally, 8 million episodes of serious disease are caused by Haemophilus influenzae type b 
(Hib) among children each year leading to an estimated one-half a million of deaths.1 In 
Bangladesh, Hib has been identified as 1 of the 3 leading etiologic agents of childhood 
meningitis.
One-quarter of the cases of confirmed Hib meningitis die, and approximately one-quarter of 
survivors experience long-term disability.2 Invasive Hib disease has been virtually 
eliminated from high-income countries where Hib conjugate vaccine has been introduced as 
part of the routine childhood immunization.3-7 The high cost of the vaccine and controversy 
about the burden of disease in Asia has delayed widespread adoption of the vaccine in this 
region. However, recent data suggest that the incidence of Hib in Asia does not differ much 
from that of Europe in the prevaccine era of 25 per 100 000 for meningitis and at least 40 
per 100 000 per year for invasive Hib disease at the age of 0-5 years.8,9 The total burden of 
Hib probably is significantly greater as nonbacteremic Hib pneumonia remains mostly 
undetected.
Most of the evidence related to Hib disease burden is hospital-based prevalence estimates 
derived from a single or few hospitals or health care facilities.10 These rates grossly 
underestimate disease incidence because they do not account for the population not served 
by these facilities, differing disease referral patterns, low lumber puncture rates, as well as 
suboptimal laboratory procedures.9
The World Health Organization now recommends Hib conjugate vaccine be incorporated in 
all routine infant immunization programs even in absence of local disease burden data.11 
The vaccine is being introduced in a number of Asian countries but few have evidence of 
effectiveness. In June 2009, the Government of Bangladesh introduced Hib conjugate 
vaccine into the national Expanded Program on Immunization (EPI), with support from 
GAVI Alliance (formerly known as the Global Alliance for Vaccines and Immunization), 
with the understanding that an increasing proportion of the vaccine cost would be borne by 
the Bangladeshi Government in subsequent years. The objective of this study was to assess 
the impact and coverage of this introduction of the Hib conjugate vaccine through the 
National EPI program on Hib meningitis and thereby permit the Government of Bangladesh 
to make informed decisions regarding future funding.
Methods
The study consisted of 2 components: hospital-based surveillance of meningitis and a 
community-based hospital catchment area assessment conducted twice (once in the 
prevaccine period and a second assessment postvaccination). We compared the incidence of 
Hib meningitis in hospitalized infants 1 year before and 1 year after the vaccine was 
introduced into the childhood immunization schedule.
Individual informed consent was obtained from the primary caretaker of the children before 
enrolling in the study. The study was approved by ethics committee at International Center 
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for Diarrheal Disease Research, B (icddr,b) and Johns Hopkins University, and exempted by 
Centers for Disease Control and Prevention ethics as it was deemed part of routine 
surveillance.
Hospital-Based Surveillance
On May 1, 2008, we initiated surveillance for Hib meningitis in 2 large pediatric hospitals in 
Dhaka, Bangladesh. Dhaka Shishu Hospital and Shishu Shasthya Foundation Hospital are 2 
of the largest pediatric hospitals in Bangladesh. They provide primary, secondary, and 
tertiary care for severe childhood illnesses. Routine investigations with lumbar puncture are 
part of the standard of care at both of the hospitals for children who present with symptoms 
of meningitis. The aim of the hospital-based surveillance was to identify children with 
meningitis and to collect clinical specimens for laboratory diagnosis. Surveillance 
physicians regularly reviewed hospital admissions and identified patients <5 years of age 
who met a meningitis clinical case definition (children with new onset of fever with either 
altered mental status, new onset of seizures, or signs of a bulging fontanelle or stiff neck).
The surveillance physicians were trained in using maps to identify and enroll patients from 
within the limits of the catchment area of the hospital (outlined below). From these patients, 
the physicians collected data on demographics and clinical course of the disease using a 
standardized questionnaire and coordinated the collection of a sample of cerebrospinal fluid 
(CSF) on admission for laboratory diagnosis of meningitis. They collected a sample of urine 
in cases where CSF collection failed or was not advised. The specimens from both hospitals 
were tested at the Dhaka Shishu Hospital microbiology laboratory. Laboratory procedures 
for detection of H influenzae included culture of blood, CSF, latex agglutination test (LAT), 
and polymerase chain reaction (PCR). The isolates were serotyped by the slide agglutination 
method using type specific antisera (Murex, Kent, United Kingdom).2 Hib was identified 
from culture negative CSF by LAT and/or PCR. Serotype of the culture negative cases was 
determined as b or non-b, by LAT and/or PCR.2,12 Laboratory procedures for the detection 
of Streptococcus pneumoniae included culture of blood or CSF.
Defining Catchment Area
We conducted surveillance within the boundaries of the primary catchment area around the 
2 surveillance hospitals. We defined the boundaries of the primary catchment area by 
identifying household locations of 100 children who had been discharged from the 
surveillance hospitals with a diagnosis of meningitis or encephalitis living within 1 hour of 
transport time from the hospitals. We consecutively enrolled children from the hospital who 
met our enrollment criteria and continued enrollment until we obtained 100 samples. Field 
researchers noted the geographical positional system co-ordinates of the house, which were 
plotted onto a map. We outlined a geographical area, which captured a majority (>80%) of 
these house locations, and labeled it as the primary catchment area of the 2 hospitals.
We superimposed a virtual grid over the catchment area, which divided it into 1748 equal 
sized 5 second (0.833°) latitude by 5 second longitude rectangles that corresponded in the 
community to an area of 142 by 153 meters. We used a random number generator to select 
100 such rectangles for community assessment. In June 2008, the field team traveled to each 
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of the selected rectangles assisted by satellite photographs and remote sensing, and 
conducted a survey before introduction of Hib conjugate vaccine in each of the households 
whose front door was within the boundaries of the 100 randomly selected rectangles whose 
residents included a child <5 years of age. Among parents who consented, the interviewers 
collected the number and date of birth of children <5 years of age who lived in the 
household. Interviewers copied the vaccinations recorded on the child’s vaccine card when a 
card was available, and asked the child’s mother to recall vaccinations if the card was 
unavailable. In addition, the interviewers asked if any of the children <5 years of age in the 
household had developed a serious illness with acute onset of fever with either convulsions 
or unconsciousness or altered mental status in the preceding year (clinical 
meningoencephalitis) and the proportion who used either of the 2 surveillance pediatric 
hospitals during this illness. We defined a suspect case of meningoencephalitis as a child 
who had a serious illness with acute onset of fever with either convulsions or 
unconsciousness or altered mental status. We repeated this cross-sectional evaluation in 
August 2010 in a new random sample of 30 rectangles to reassess vaccine coverage after 
introduction of the Hib conjugate vaccine into the national EPI program. We used a smaller 
sample for the 2010 survey because it provided sufficient precision to estimate 
immunization coverage; we did not aspire to reassess hospital utilization.
Hib Vaccination Program
Hib conjugate vaccine in pentavalent formulation, Quinvaxem (diphtheria-tetanus-pertussis 
(DTP)-hepatitis B-Hib fully liquid combined vaccine) manufactured by Novartis (Basel, 
Switzerland) was introduced into the Bangladesh EPI program on June 10, 2009. The 
vaccine was targeted at children aged 6, 10, and 14 weeks. The first children eligible to 
receive a 6-week dose of the pentavalent vaccine on June 10, 2009 were born on April 15, 
2009, and received their third dose by August 2009.
Pre- and Postvaccine Periods
We designated cases among children born between May 1, 2008 (commencement of our 
hospital based surveillance) to April 15, 2009, as belonging to our prevaccine period, and 
children born on or after April 19, 2009- May 15, 2011, as belonging to our postvaccine 
period, based on eligibility to have received Hib conjugate vaccine. We restricted our 
analysis among children <12 months of age as there was only 1 year of postintroduction data 
available at the time of reporting, and this is the age group most at risk for Hib meningitis.
Data Analyses
This surveillance is designed to measure Hib disease in children < age 5 years, but in this 
post-Hib conjugate vaccine introduction assessment, we limited the analysis to children ≤1 
year of age because so few children had reached an older age, and we wanted to compare 
children of similar age before and after vaccine introduction. We calculated person-time 
denominators as the years of follow-up from birth until the outcome of interest: meningitis 
or death, or 1-year of age or the end of study follow-up. We aggregated observed person-
time for children in surveyed rectangles and then projected for the total number of infants in 
the entire catchment area. We defined a case of confirmed Hib meningitis as confirmation 
by culture, LAT or PCR of Hib in the CSF or LAT for Hib antigen in urine at the dilution 
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≥1:16 in a child presenting with clinical meningitis. We also considered a case of clinical 
meningitis with Hib isolated from blood culture as confirmed Hib meningitis. We classified 
a case as purulent meningitis if a child who presented with clinical meningitis had CSF with 
a cell count of >100 polymorphonuclear leukocytes cells/mm3. We calculated crude 
incidence by dividing the number of confirmed Hib meningitis cases by the total person-
time contributed by infants during the pre- and the postvaccine periods. We then adjusted 
these crude rates by the proportion of suspect meningoencephalitis cases in the catchment 
area who sought care at the 2 surveillance hospitals. To analyze the impact of vaccine 
introduction and calculate the vaccine preventable incidence rate, we took the difference in 
incidence of Hib and purulent meningitis before and after introduction of the vaccine. We 
evaluated the incidence of culture confirmed pneumococcal meningitis as a comparison that 
would be affected by any change in surveillance but would not be impacted by the 
introduction of the Hib conjugate vaccine. We defined a case of pneumococcal meningitis as 
confirmed by blood or CSF culture for a child presenting with clinical meningitis. We 
analyzed our data using Stata v. 8.2 (College Station, Texas).
Results
Characteristics and Health Care Seeking Pattern of Meningoencephalitis Cases Detected 
in the Community
In 2008, the field team approached households in 98 of the randomly selected rectangles. 
Two of the rectangles were in areas under army supervision, and the authorities did not grant 
permission for house to house interviews. Among 11 380 households in the 98 rectangles, 
9632 had children < age 5 years, and the field team secured consent and completed 
interviews in 9458 (98%). In these 9458 households, parents described 149 episodes of 
illness among their children <5 years of age that met the suspect meningoencephalitis case 
definition. Patients who sought care at the surveillance hospital were similar, in terms of 
severity of disease (seizures >30 minutes; or altered mental status >6 hours; or 
unconsciousness >1 hour), to patients who did not seek care there (Table I). Among the 
cases that sought care at the surveillance hospital, 65% were male compared with 45% 
among the cases who did not seek care at the hospital (P = .02). Over their entire illness 
duration, 48 (32%) cases sought care at either of the 2 catchment area hospitals. Among the 
cases of suspect meningoencephalitis who did not seek care at the catchment hospital, 57% 
sought care from other Bachelor of Medicine and Bachelor of Surgery qualified physicians 
in the vicinity (Table I).
Hospital-Based Surveillance
In the hospital-based surveillance, 958 patients <1 year of age arising from the catchment 
area of the hospitals were enrolled between May 1, 2008 and September 30, 2011, as 
possible cases of Hib meningitis. Among the 958 enrollees, 13 cases had laboratory 
evidence of Hib meningitis with 11 cases detected in the prevaccine period and 2 cases 
detected in the postvaccine period. Among these 2 cases, 1 had received only 1 dose of the 
pentavalent vaccine and the other had not received the vaccine at all. Seven (54%) of the 
cases were between 1-5 months and 6 (46%) were between 6-11 months. Six of the 11 cases 
(47%) were detected by culture alone with the remaining episodes being diagnosed by Hib 
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antigen CSF LATs (38%) and urinary latex agglutination (15%). The median CSF white cell 
count for cases was 600 cells/mm3. There were no deaths recorded among the patients with 
laboratory-confirmed Hib meningitis (Table II).
Vaccine Preventable Incidence of Hib and Pyogenic Meningitis after Introduction of Hib 
Conjugate Vaccine in the National Immunization Program
The incidence of laboratory-confirmed Hib meningitis per 100 000 child-years among 
infants in the prevaccine period was 91.9 (Table III). The incidence declined to 15.7 cases 
per 100 000 child-years in infants a year after introduction of the vaccine. From the 
difference in rates between the pre- and postvaccine periods, the calculated vaccine 
preventable incidence of laboratory diagnosed Hib meningitis was 76 per 100 000 child-
years of observation (95% CI 18-135 per 105 child-years) and that of laboratory-confirmed 
purulent meningitis was 500 per 100 000 child-years (95% CI 203-799 per 105 child-years). 
The preventable proportion of Hib meningitis was 83% and that of purulent meningitis was 
30%. The annual incidence of laboratory-confirmed pneumococcal meningitis did not 
significantly differ between the pre- and postvaccine periods (Table III).
In the prevaccine immunization coverage survey, conducted during 2008-2009, 95% of 
children had received the third dose of DTP by the age of 12 months. Likewise, 93% of 
similarly-aged children had received the third dose of the pentavalent vaccine in the 
postvaccine period survey conducted in 2010-2011.
Discussion
In contrast to the belief that Hib disease is rare in Asia,13-17 our study demonstrated a high 
prevaccine incidence of confirmed Hib meningitis (92 per 100 000) in Bangladeshi infants, 
with an even higher vaccine preventable annual incidence of 500 per 100 000 child-years. 
Moreover, the Hib conjugate vaccine prevented over 6 times as many cases of purulent 
meningitis as laboratory-confirmed Hib meningitis. Extrapolating the vaccine preventable 
incidence rate to the 2.8 million <1-year-olds18 living in Bangladesh suggests that the 
vaccine prevented about 14 000 cases attributable to Hib meningitis in the entire country.
Less Hib meningitis in Bangladesh means increased child survival and child health. Children 
with laboratory-confirmed Hib meningitis have a case fatality of 22%, and another 24% of 
the cases develop long-term neurologic sequelae.2 The results of this study suggest that an 
estimated 3121 infant deaths and 3405 cases of neurologic sequelae resulting from Hib 
meningitis were prevented annually. However, we do not know if children who were 
diagnosed as purulent meningitis but attributable to Hib who were not diagnosed as Hib 
meningitis by the laboratory have the same outcome as cases who have been diagnosed with 
confirmed Hib meningitis.
These data provide insight on how the burden of Hib can be easily underestimated. Most of 
the cases of purulent meningitis that were due to Hib were negative by culture, LAT, and 
PCR, as shown by the large drop in cases of purulent meningitis following Hib conjugate 
vaccine introduction. Even in this setting of an excellent microbiology laboratory, the vast 
majority of cases of Hib meningitis prevented by the vaccine were not confirmed as Hib 
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and, therefore, not attributed to Hib meningitis. The sensitivity of the Hib diagnostic tests 
are not 100%, especially in the context of high levels of antimicrobial treatment before 
samples are obtained. In a previous study in the Dhaka Shishu Microbiology laboratory, 
53% of CSF samples had evidence of antibiotics.19 India does not detect much Hib 
meningitis in diagnostic laboratories,15 and hence, many health authorities conclude that 
there is not much Hib meningitis in their country, a conclusion that these data from 
Bangladesh suggest is likely erroneous.
Our observations demonstrate that even very high-performing laboratories will not detect the 
vast majority of the cases of Hib meningitis, and, therefore, only considering 
microbiologically-confirmed Hib cases will drastically underestimate the burden of disease. 
Moreover, meningitis represents only part of the burden of Hib disease. An estimated 5 
cases of pneumonia occur for each case of meningitis.20,21 Extrapolating the vaccine 
preventable estimate of 500 cases of Hib meningitis per 100 000 would estimate the 
incidence of Hib pneumonia in Bangladesh at 4000 cases per 100 000 child-years and 
extrapolating this rate further to the 2.8 million <1-year-olds18 living in all Bangladesh 
suggests that if the vaccine is as effective in preventing pneumonia as it was in preventing 
meningitis the vaccine prevented about 112 000 cases of Hib pneumonia in the entire 
country.
The study demonstrated that routine immunization with Hib conjugate vaccines produced a 
significant reduction in the burden of Hib meningitis even in its first year of introduction. 
We used the detection of invasive pneumococcal meningitis as a comparison indicator for 
secular trends in prior treatment, surveillance practices, and laboratory methods that could 
have offered alternative explanations for this reduction. The incidence of pneumococcal 
meningitis remained the same but Hib and purulent meningitis dropped notably, which 
strongly suggests that the reductions in purulent and Hib meningitis were due to the Hib 
conjugate vaccine introduction. High levels of coverage for DTP 3/pentavalent 3 also 
enabled us to show impact of disease reduction in the first year of introduction.
Hib conjugate vaccine reduces nasopharyngeal colonization in vaccinated children, which 
also protects unvaccinated children by reducing exposure to the Hib pathogen. Routine 
introduction of the Hib conjugate vaccine in the Gambian EPI in 1997 demonstrated that 
direct impact of the vaccine contributed only 40% of the total population effects that were 
observed.22 Herd protection can result from the reduction in the transmission of the target 
pathogen in a population in which a proportion of the population become immune due to 
vaccination,22 and represent important additional benefits of investment in vaccination, 
especially by low-income countries with limited resources.
A primary limitation of the study is that we have calculated the impact of the vaccination 
program only among children <12 months old because this was when we had the maximum 
person-time of vaccinated children and this is the age group in which incidence is highest. 
This could underestimate the vaccine impact because, as the vaccination program continues, 
greater herd immunity would be expected to further reduce circulation of the bacteria by 
reducing nasopharyngeal carriage and further reduce burden even among the unvaccinated 
<12-month-olds. However, as seen from the age structure of Hib cases detected in earlier 
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hospital-based studies conducted in Bangladesh,2 most of the cases of meningitis occurred 
during the first year of life, and, hence, our analysis provides an early but useful and 
conservative estimate of the impact of the program.
Second, our adjusted incidence assumes that children who sought care at the surveillance 
hospital had a similar likelihood of having Hib meningitis as those that sought care 
elsewhere. Children who received care at the surveillance hospitals and children who did not 
had similarly severe symptoms. If there was a systematic difference in the proportion of 
cases of Hib seeking care inside versus outside the surveillance hospital this may affect the 
adjusted incidence estimates, but we would expect that any such effect would be equivalent 
in the pre- and postvaccine periods, and therefore, would not bias the impact assessment.
Third, our incidence and impact was calculated in a particular urban area of the country. 
This may not reflect the national burden of Hib disease as rates of disease may differ in 
other parts of the country where people live under different living conditions; however, we 
have no reason to believe that rates would be markedly different elsewhere in the country.
Fourth, not every child received a lumbar puncture. The rate of lumber puncture among 
cases of suspected meningitis in the surveillance hospitals in the pre- and postvaccine 
periods were 71% and 73%, respectively (unpublished data from hospital surveillance). 
Children who did not receive a lumbar puncture could not become a laboratory-confirmed 
case of purulent meningitis. Therefore, we almost certainly underestimated the burden of 
purulent meningitis. However, our data demonstrate that the rates of lumbar puncture were 
similar in the year before and the year after vaccine introduction, and therefore, this would 
be expected to consistently underestimate burden of Hib disease.
This study provides credible estimates of burden of Hib meningitis and shows initial, 
conservative effectiveness of the Hib conjugate vaccine in its first year of introduction 
through the national EPI. The study has important implications for other low-income 
countries and can act as an important tool to encourage the introduction of Hib conjugate 
vaccine into routine immunization programs of countries where the burden of Hib disease is 
high but there is limited capacity to conduct population-based surveillance. The impact of 
the vaccination program on the reduction of Hib meningitis provides evidence to support 
continuation of the Hib conjugate vaccine in the EPI schedule of Bangladesh. Further cost 
effectiveness studies and studies that evaluate impact after several years of implementation 
could provide further evidence as the stewards of Bangladesh and neighboring countries 
consider retention of Hib conjugate vaccine in the EPI schedule.
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Table I
Demographic characteristics and reported clinical signs of suspect meningoencephalitis patients by admission 




(N = 48) # (%)
Not admitted at
study hospital
(N = 101) # (%) P value
Male 31 (65) 45 (45) .02
Age-group
 <6 mo 2 (4) 2 (2) .48
 6-12 mo 0 (0) 6 (6) .08
 >12 mo 46 (96) 93 (92) .36
Reported clinical signs
 Seizures >30 min 22 (46) 40 (40) .49
Altered mental status >6 h 30 (63) 70 (69) .47
 Unconsciousness >1 h 14 (29) 27 (27) .79
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Table II
Characteristics of laboratory-confirmed Hib meningitis cases (N = 13), Dhaka, Bangladesh, 2011
Characteristics Number (%)
Clinical description
 Fever 13 100
 Convulsion >30 min 2 14
 Reduced level of consciousness 3 23
 Bulging fontanelle 6 46
CSF white blood count, median 600
Age at diagnosis
 0-5 mo 5 38
 6-11 mo 8 62
Laboratory results
 CSF culture-confirmed 6 47
 CSF latex-confirmed 5 38
 Urinary latex-confirmed (1:32) dilution 2 15
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